Bristol Myers Squibb reports two trials: what it means for Bristol Myers Squibb stock
Published on 10/14/2026 at 09:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTwo trials shape the pipeline
- Bristol Myers Squibb announced two Phase 3 trial updates on October 12, 2026.
- Admilparant met the primary endpoint at 60 milligrams, while the 120 milligram dose was not statistically significant.
- Bristol Myers Squibb stock traded at EUR 50.71 at 9:37 a.m. CEST at Lang & Schwarz on October 14, 2026.
- Third-quarter results are scheduled for October 29, 2026.
Bristol Myers Squibb (ISIN US1101221083) reported two Phase 3 trial updates on October 12, 2026. Bristol Myers Squibb said the 60 milligram dose of admilparant met the primary endpoint in the ALOFT-IPF trial, while the 120 milligram dose slowed the decline in forced vital capacity but was not statistically significant.
Two Phase 3 results
The ALOFT-IPF trial enrolled approximately 1,255 adults and evaluated both doses against placebo for at least 52 weeks. The company said discontinuations caused by adverse events were low and similar to placebo across the two admilparant groups.
A separate October 12 release covered ACTION-1, a Phase 3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors. Bristol Myers Squibb said the study met its primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival.
What does the pipeline mean?
The two updates add clinical milestones to a portfolio facing upcoming patent and competition pressure. The different dose outcomes in ALOFT-IPF make the detailed data and regulatory discussions important for assessing admilparant's commercial potential.
Revenue and earnings context
For the quarter ended June 30, 2026, Bristol Myers Squibb reported USD 12.97 billion in revenue and USD 3.32 billion in net profit, according to The Globe and Mail. The same report cited quarterly earnings per share of USD 2.04, compared with a consensus estimate of USD 1.60.
Three dated pipeline milestones
On June 30, 2026, the quarter ended with USD 12.97 billion in revenue and USD 3.32 billion in net profit, as reported by The Globe and Mail. On October 12, 2026, ALOFT-IPF produced a statistically significant result at 60 milligrams, while ACTION-1 also met its primary endpoint on the same date.
Upcoming dates
Bristol Myers Squibb is scheduled to report third-quarter 2026 results on October 29, 2026, with an 8:00 a.m. ET conference call. The ALOFT-PPF trial is expected to provide topline results in early 2027.
Stock price and market value
Bristol Myers Squibb stock was trading at EUR 50.71 at Lang & Schwarz on October 14, 2026, at 9:37 a.m. CEST. The finance quote showed a primary-market reference of USD 56.67 at the New York Stock Exchange on October 13, 2026, with a market capitalization of USD 115.8 billion and a 52-week range of USD 42.52 to USD 68.64.
The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.
Bristol Myers Squibb stock at a glance
- Company: Bristol-Myers Squibb Company
- ISIN: US1101221083
- WKN: 850501
- Ticker: BMY
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 14, 2026, 9:37 a.m. CEST): EUR 50.71
- Market capitalization: USD 115.8 billion (as of October 13, 2026)
- 52-week range: USD 42.52-USD 68.64 (as of October 13, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Index membership: S&P 500
- Next earnings date: October 29, 2026
